Japan Bioinformatics Market Analysis Report [2022-30] I Insights10

Japan Bioinformatics Market Analysis

$ 3999

The Japan Bioinformatics market is projected to grow from $0.95 Bn in 2022 to $3.31 Bn by 2030, registering a CAGR of 16.8% during the forecast period of 2022 - 2030. The main factors driving the growth are rising government funding, an increase in genomics and proteomics research projects, and a developed healthcare system. The market is segmented by technology and by application. Some of the major players include Fujitsu (JPN), NEC (JPN), M3 (JPN), IBM Life Sciences, BioWisdom Ltd.

ID: IN10JPHS001 CATEGORY: Healthcare Services GEOGRAPHY: Japan

Buy Now

Japan Bioinformatics Market Executive Summary

The Japan Bioinformatics market is projected to grow from $0.95 Bn in 2022 to $3.31 Bn by 2030, registering a CAGR of 16.8% during the forecast period of 2022 - 2030. In 2019, Japan's healthcare spending decreased to 10.74% of GDP from 10.75% in 2018 but the per capita increased to $4,360 in 2019 from $4,256 in 2018. Japan's healthcare expenditure is higher compared to the average for developed countries.

Bioinformatics is the management and analysis of biological data through the use of computer technology. It comprises collecting, analyzing, and sharing biological data. It entails the use of computer programs to ascertain the roles of genes and proteins, establish evolutionary linkages, and forecast the three-dimensional forms of proteins. The market for bioinformatics in Japan is moving in the direction of a greater acceptance of bioinformatics tools and technologies across a variety of industries, including healthcare, pharmaceuticals, and biotechnology.

japan bioinformatics market analysis

Market Dynamics

Market Growth Drivers

A number of factors, including rising government funding for bioinformatics research through the Japan Science and Technology Agency (JST) and the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), an increase in the number of genomics and proteomics research projects, and a rise in the use of bioinformatics tools in the pharmaceutical and biotech sectors, have contributed to the rapidly expanding bioinformatics market in Japan. Further, the developed healthcare system in Japan has fueled the demand for bioinformatics products in the healthcare sector. Electronic health records and the use of big data in healthcare are driving the growth of the bioinformatics market in Japan.

Market Restraints

The bioinformatics market in Japan lacks data exchange and collaboration among its various stakeholders and strict laws protecting individuals' privacy, which might make it challenging for businesses to get and use data for bioinformatics research and development. This might hinder the Japanese bioinformatics market's expansion.

Competitive Landscape

Key Players

Fujitsu (JPN)
NEC (JPN)
M3 (JPN)
IBM Life Sciences
BioWisdom Ltd.

Notable Recent Deals

July 2022: Fujitsu announced plans to acquire Enable Professional Services, Asia-Pacific’s largest independent service now consultancy, to strengthen its service management advisory, consulting, and delivery services capability. With this acquisition, Enable Professional Services will function as a stand-alone Fujitsu company under the continued leadership of Bruce Hara., and will be re-branded ‘Enable, a Fujitsu company’.

July 2019: NEC announced the acquisition of OncoImmunity AS, a bioinformatics firm that creates specialized machine learning software to aid in the fight against cancer. This acquisition was necessary to boost the capabilities and resources that support the creation of its pipelines for customized immunotherapy. While NEC OncoImmunity AS will keep providing its neoantigen prediction services, NEC will continue to concentrate on drug discovery.

Healthcare Policies and Regulatory Landscape

The Act on the Protection of Personal Information (APPI), which governs the management and protection of personal information in Japan, serves as the primary regulatory framework for bioinformatics in the country. All organizations that handle personal information, including bioinformatics businesses and research institutions, are subject to this regulation.

Clinical trial regulations, the Act on the Protection of Personal Information in Medical Institutions (APPMI), which governs the handling of health information and medical records, the drug approval process, and medical device regulations are additional restrictions that influence the regulatory landscape of the bioinformatics market in Japan. These rules are in place to guarantee that patients and consumers can rely on bioinformatics goods and services to be trustworthy, efficient, and safe.

Reimbursement Scenario

The National Health Insurance (NHI) system and the government set reimbursement guidelines for the bioinformatics sector in Japan. Numerous medical services, including bioinformatics services, are covered by the NHI system and are funded by a combination of taxes, premiums, and out-of-pocket payments., The reimbursement rates may change depending on the kind of service, the facility providing the service, and the patient's health, and reimbursement rates may vary based on the type of service, the facility providing the service, and the patient's condition.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Bioinformatics Market Segmentation

By Technology (Revenue, USD Billion):

Knowledge Management Tools
Bioinformatics Platforms
Bioinformatics Services

By Application (Revenue, USD Billion):

Metabolomics
Molecular phylogenetics
Transcriptomics
Chemoinformatic & drug design
Genomics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.